Cold Kit Formulation for 68Ga-Edotreotide Without Sequestering Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions for [68Ga]Ga-edotreotide require the use of toxic sequestering agents like 1,10-phenanthroline and metal inhibitors, which pose hazards during manufacturing and have toxic effects on humans, making them unsuitable for stable and safe radiolabeling and distribution.
Innovation Solution
A novel cold-kit formulation is developed, comprising a single stabilizer, a single buffer, and no sequestering agents, allowing for the preparation of stable, radiochemically pure 68Ga complexes of edotreotide that can be easily radiolabeled in a radiopharmacy using Ga-68 eluted from a generator or cyclotron.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If toxic sequestering agents like 1,10-phenanthroline are used to improve radiolabeling efficiency, then radiochemical purity is improved, but human safety and manufacturing safety deteriorate
Solution Approach 1:
The patent removes toxic sequestering agents (1,10-phenanthroline, DTPA) from the radiolabeling composition entirely. Instead, it uses a simplified buffer system with sodium acetate and sodium citrate to achieve radiolabeling, extracting the harmful components while maintaining the essential function of pH control and complexation.
Solution Approach 2:
The patent changes the chemical parameters of the composition by replacing toxic chelating agents with a buffer system based on sodium acetate and sodium citrate. This parameter change maintains the necessary pH range (4.0-6.0) for effective 68Ga radiolabeling while eliminating toxicity, achieving both radiochemical purity and safety.
2Stability of the object's composition
If multiple stabilizers and sequestering agents are used to stabilize high concentration DOTA complexes, then composition stability is improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent extracts unnecessary components from the composition by using only a single stabilizer (sodium ascorbate) instead of multiple stabilizers and sequestering agents. This simplification maintains composition stability during storage and radiolabeling while reducing manufacturing complexity.
Solution Approach 2:
The buffer system (sodium acetate and sodium citrate) performs multiple functions simultaneously: it controls pH, stabilizes the DOTA complex, and enables effective radiolabeling with 68Ga. This multi-functionality eliminates the need for separate stabilizers and sequestering agents, reducing complexity while maintaining stability.
3Manufacturing precision
If ready-to-use injectable solution is prepared with short shelf life, then radiochemical purity is maintained, but distribution capability and accessibility deteriorate
Solution Approach 1:
The patent prepares a lyophilized powder formulation in advance that is stable during storage and transportation. The actual radiolabeling with 68Ga is performed at the point of use in the radiopharmacy, ensuring high radiochemical purity while enabling distribution to distant locations. The lyophilized form can be stored for extended periods before radiolabeling.
4Productivity
If complex two-vial composition with multiple agents is used, then radiolabeling efficiency is improved, but ease of manufacture and ease of operation deteriorate
Solution Approach 1:
The patent merges multiple functions into a single simplified buffer composition containing sodium acetate, sodium citrate, and sodium ascorbate. This unified composition provides pH control, stabilization, and radiolabeling capability in one formulation, eliminating the need for separate stabilizers and sequestering agents, thereby simplifying manufacturing while maintaining radiolabeling efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution achieves high radiochemical purity and stability of the 68Ga-labeled edotreotide compositions, eliminating the need for toxic sequestering agents and enabling safe and efficient distribution to radiopharmacies and hospitals for PET imaging and therapy.
Implementation Method 1
The radionuclide 68Ga is complexed by the functional chelator DOTA, which acts as a hexadentate chelator with octahedral geometry, coordinating the 68Ga to four nitrogen as well as two carboxylic groups
Data Source
AI summary
The present invention relates to a pharmaceutical cold kit composition comprising a chelating agent linked to somatostatin receptor binding organic moiety, a stabilizer, a buffer, and a caking agent or bulking agent, wherein the composition is free of sequestering agent. Further, the present invention also relates to the process of preparing reconstituted or radiolabeled solution composition having high in use stability and radiochemical purity and use thereof for diagnostic and/or therapeutic purposes.